Based upon the vibrant gut immunological ecosystem, Rise Therapeutics has developed a platform that enables oral delivery of immunological-based, biological therapies. The oral delivery platform, TriPartite X (TPX), is a novel DNA assembly approach that allows for creation of recombinant probiotics to escort targeted protein therapies to the site of action, the intestinal space. TPX is a large step forward in the context of biologics drug development, allowing us to step away from regular injections and infusion strategies for a more convenient ‘pill-based’ oral delivery perspective for biological therapies. TPX can be utilized to deliver a variety of protein-based therapeutics, and Rise has interest in exploring applications with potential partners that have protein-based drug candidates that they want to develop as orally-available targeted biologics.
Our bodies co-exists with a community of trillions of microbes, the microbiota, that form a symbiotic relationship with us. It is estimated that there are three times the number of microbiota compared to human cells. The microbiota are important for supporting human health and preventing disease. As a result, dysregulation of our microbiota can play a role in immunological related diseases including autoimmunity and cancer. Thus, understanding the microbiome can lead to novel targets for disease therapy. In collaboration with our founders and key scientific leaders, Rise Therapeutics has embarked on strategies that allow for identification of unique and novel microbiome-related immunological pathways and targets. Based upon these discoveries, Rise then uses its proprietary delivery technology to design targeted protein-based therapies that are encapsulated and delivered orally for treatment of a wide range of diseases.
The immune system is an important defense mechanism that protects us against a wide range of pathogens. Human immunology is a highly regulated and complex process that has evolved in a manner that allows for us to distinguish host from pathogen. Nowhere in the body is the immune system more ‘vibrant’ than in the intestinal tract where the majority of the microbiota reside. It is estimated that more immunological signals are processed in the gut in one day than in the rest of the entire body in a lifetime. Thus, it is no surprise that the gut immunological ecosystem and the immunological interface between the micriobiota and the human immune cells can have such important functionality on the local and systemic immune processes. In order for the microbiota to persist, the immune system must be held in check and prevented from attacking the very process that helps support our health and well-being. Therefore, as we better understand how these key processes support this lack of reactivity, or tolerance, we can design immunological-based drugs that can intervene to treat such diseases as autoimmunity and cancer.